StefanieMasakoUedaMD
Obstetrics & Gynecology • San Francisco, CAGynecologic Oncology
Assistant Professor, Obstetrics/Gynecology & Reproductive Science, UCSF School of Medicine
Are you Dr. Ueda?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 48 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1600 Divisadero St
A749
San Francisco, CA 94143Phone+1 415-885-7561
Summary
- Dr. Stefanie Ueda, MD is an obstetrician/gynecologist in San Francisco, California. She is currently licensed to practice medicine in California, Maryland, and Hawaii. She is affiliated with UCSF Medical Center, Zuckerberg San Francisco General Hospital and Trauma Center, and Providence Santa Rosa Memorial Hospital.
Education & Training
University of HawaiiResidency, Obstetrics and Gynecology, 2002 - 2006
New York University School of MedicineClass of 2002
Certifications & Licensure
CA State Medical License 2006 - 2026
HI State Medical License 2002 - 2026
MD State Medical License 2007 - 2011- American Board of Obstetrics and Gynecology Obstetrics & Gynecology
- American Board of Obstetrics and Gynecology Gynecologic Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
- Fellow (FACOG) American Congress of Obstetricians and Gynecologists
Publications & Presentations
PubMed
- Feasibility of neoadjuvant chemotherapy for bulky early stage to stage IIIB cervical cancer in Uganda.Jane Namugga, Janice Wong, Carolyn Nakisige, Anthony Okoth, Judith Ajeani
Gynecologic Oncology Reports. 2024-12-01 - Evidence-based prescribing of opioids after laparotomy: A quality-improvement initiative in gynecologic oncology.Allison H Kay, Rachel Levy, Nancy Hills, Allyson Jang, Alison Mcgough-Maduena
Gynecologic Oncology Reports. 2024-06-01 - Synthetic Lethality Beyond BRCA: A Phase I Study of Rucaparib and Irinotecan in Metastatic Solid Tumors With Homologous Recombination-Deficiency Mutations Beyond BRCA1/2.Erica S Tsang, Mallika S Dhawan, Romain Pacaud, Scott Thomas, Jennifer Grabowsky
JCO Precision Oncology. 2024-06-01
Press Mentions
Covered CaliforniaJanuary 22nd, 2016
Professional Memberships
- Fellow
